WBI-2100: A Novel Anti-cancer Compound with Neutropenia-prevention
WBI-2100 is being developed by Welichem as a treatment for solid cancers both as a
monotherapy and synergistically in combination with other chemotherapies. Unlike other
chemotherapeutic agents, WBI-2100 boosts neutrophil levels and prevents chemotherapy-
induced neutropenia (CIN). There are no other anti-cancer drugs possessing such dual activities.
WBI-2100’s anti-cancer activity has been demonstrated in various mouse tumour models (lung,
breast, kidney, liver, pancreas, ovarian cancers and melanoma) both as a monotherapy and as a
synergistic combination-therapy with Cisplatin, Taxol, Gemcitabine, or Dacarbazine.
It seems that WBI-2100 possesses multiple modes of action as a novel anti-cancer drug
candidate. The cytotoxicity of WBI-2100 is more selective for solid cancer cells over
hematological cancer cells. Its anti-metastasis and anti-angiogenesis activities have been
demonstrated in vitro and in vivo.
The unique nature of WBI-2100 is it’s property of boosting neutrophils on top of its anti-cancer
activity which has been demonstrated in different animal species. Such stimulatory effects are
specific for neutrophils, and other hematopoietic cells are not affected by the WBI-2100
treatment. More interestingly, when WBI-2100 is combined with the chemotherapeutic drug
cyclophosphomide, chemotherapy-induced neutropenia is prevented. These combined activities
of WBI-2100 as a novel cancer drug candidate that also stimulates neutrophils suggests that it
has the potential of being a unique cancer chemotherapy that negates the serious side effects
normally experienced by patients undergoing cancer chemotherapy. In theory, by having the
unique dual activity, WBI-2100 can be combined with any chemotherapeutic cancer drugs to
increase other drug’s anti-cancer efficacy and at the mean time to prevent or treat the CIN. WBI-
2100 could potentially also be developed as a small molecule treatment for CIN.